Advertisement

International Journal of Clinical Pharmacy

, Volume 36, Issue 5, pp 863–864 | Cite as

Oral chemotherapy prescription safety practices in Europe

  • David Conde-EstévezEmail author
  • Joan Albanell
Commentary

Impact of findings on practice

  • Two recent surveys on oral chemotherapy from Spain and France provide novel data in a European setting on this field.

  • Depending on the country, oral chemotherapy can be dispensed by community pharmacists or by hospital pharmacists, with notable differences in their involvement in the safety practices.

  • It is valuable to have a hospital pharmacist with experienced in oncology to be directly involved in the education also when an oral antineoplastic agent is dispensed to minimize potential errors, improve patient outcomes and compliance.

Commentary

Recently, Bourmaud et al. [1] published a very well conducted study on oral chemotherapy prescription survey in France. This study, together with a recent publication of our group on oral chemotherapy safety and adherence practices in Spain, provides novel data in a European setting on this field [2]. We believe it could be instrumental to briefly compare both studies to understand similarities as well as...

Keywords

Community Pharmacist Safety Practice Hospital Pharmacist Oral Chemotherapy Double Check 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

The authors would like to thank Dr. Aurelie Bourmaud for providing further information about the role of community pharmacists and the dispensing of oral chemotherapy in France. The study of reference is an initiative born in a consolidated group of hospital pharmacists who work to improve quality of oncohematological care, the Spanish Group for the Development of Oncological Pharmacy (GEDEFO, Grupo Español para el Desarrollo de la Farmacia Oncológica).

Conflicts of interest

None.

References

  1. 1.
    Bourmaud A, Pacaut C, Melis A, Tinquaut F, Magne N, Merrouche Y, et al. Is oral chemotherapy prescription safe for patients? A cross-sectional survey. Ann Oncol. 2014;25:500–4.Google Scholar
  2. 2.
    Conde-Estevez D, Salas E, Albanell J. Survey of oral chemotherapy safety and adherence practices of hospitals in Spain. Int J Clin Pharm. 2013;35:1236–44.PubMedCrossRefGoogle Scholar
  3. 3.
    Weingart SN, Flug J, Brouillard D, Morway L, Partridge A, Bartel S, et al. Oral chemotherapy safety practices at US cancer centres: questionnaire survey. BMJ. 2007;334:407.PubMedCrossRefPubMedCentralGoogle Scholar
  4. 4.
    Keely JL. Pharmacist scope of practice. Ann Intern Med. 2002;136:79–85.PubMedCrossRefGoogle Scholar
  5. 5.
    Colomer R, Alba E, Gonzalez-Martin A, Paz-Ares L, Martin M, Llombart A, et al. Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology (SEOM). Ann Oncol. 2010;21:195–8.PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie 2014

Authors and Affiliations

  1. 1.Department of PharmacyHospital Universitari del MarBarcelonaSpain
  2. 2.Hospital del Mar Medical Research Institute (IMIM)BarcelonaSpain
  3. 3.Department of Medical OncologyHospital del MarBarcelonaSpain
  4. 4.Pompeu Fabra UniversityBarcelonaSpain

Personalised recommendations